Acceleron reports preliminary Phase II data for ACE-083 in FSHD

Acceleron Pharma Inc. (NASDAQ:XLRN) reported preliminary data from Part 1 of a Phase II trial evaluating ACE-083 to treat facioscapulohumeral muscular dystrophy (FSHD). The company expects to start Part 2 of the trial next quarter and present additional Part 1 data this year.

The open-label first part of the trial is evaluating 150, 200 and up to 250 mg intramuscular ACE-083 every three weeks in up to 36 patients. The double-blind, placebo-controlled second part of the trial is evaluating up to 250 mg intramuscular ACE-083 every three weeks...